Screener
G&A at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Apogee Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Apogee Therapeutics, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 7:20 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-215698
| Line item | THREE MONTHS ENDEDMARCH 31, 2026 | THREE MONTHS ENDEDMARCH 31, 2025 |
|---|---|---|
| Operating expenses: | ||
| Research and development (1) | $60,819 | $46,387 |
| General and administrative | 21,953 | 16,709 |
| Total operating expenses | 82,772 | 63,096 |
| Loss from operations | (82,772) | (63,096) |
| Other income, net: | ||
| Interest income, net | 8,740 | 7,840 |
| Total other income, net | 8,740 | 7,840 |
Item 6. [Exhibits](#item_6_exhibits) [71](#item_6_exhibits)
FAQ
- What is Apogee Therapeutics, Inc.'s G&A?
- Apogee Therapeutics, Inc. (APGE) reported G&A of $21.95M in Q1 2026.
- How has Apogee Therapeutics, Inc.'s G&A changed year-over-year?
- Apogee Therapeutics, Inc.'s G&A increased by 31.4% year-over-year, from $16.71M to $21.95M.
- What is the long-term trend for Apogee Therapeutics, Inc.'s G&A?
- Over 2 years (2023 to 2025), Apogee Therapeutics, Inc.'s G&A has grown at a 69.8% compound annual growth rate (CAGR), from $24.58M to $70.88M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Apogee Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude